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Glucagon response to insulin-induced hypoglycaemia is impaired in diabetes, but the 
mechanism is not established. Pancreatic A cell hyporesponsiveness to adrenergic or 
cholinergic stimulation could contribute to the impairment. We therefore compared the 
plasma glucagon responses to intravenous infusion of adrenaline (1200 ng kg-' min-' for 
20 min) or to intravenous injection of the cholinergic agonist carbachol (50 ,ug kg-') in 
chloral hydrate-anaesthetized rats made diabetic with the use of streptozotocin 
(80 mg kg-' subcutaneously) 6 weeks before and in anaesthetized control rats. Insulin 
was infused intravenously to reduce plasma glucose levels to below 1.8 mmol L-'. As 
expected, the plasma glucagon response was reduced by - 45 yo in streptozotocin- 
diabetic rats compared with controls ( P  = 0.045). During adrenaline infusion, plasma 
glucagon levels increased by 277 f 92 pg mL-' in controls (P = 0.009) and by 
570 f 137 pg mL-' in the diabetic rats ( P  = 0.002). Thus, the plasma glucagon response 
to adrenaline was approximately doubled in the diabetic rats ( P  = 0.045). Following 
carbachol injection, plasma glucagon levels were raised by 121 1 i 208 pg mL-' 
(P < 0.001) in controls but only by 555 242 pg mL-' in the diabetic rats ( P  = 0.049). 
Thus, the plasma glucagon response to carbachol was impaired by - 58% in the 
diabetic rats (P = 0.028). We conclude that carbachol-stimulated glucagon secretion is 
impaired concomitantly with the impaired glucagon response to hypoglycaemia in 
streptozotocin-diabetic rats, whereas adrenaline-induced glucagon secretion is exag- 
gerated. We suggest that a reduced pancreatic A cell responsiveness to cholinergic 
stimulation could contribute to the impairment of the glucagon response to insulin- 
induced hypoglycaemia in diabetes. 
Key words : adrenaline, cholinergic, diabetes, glucagon secretion, hypoglycaemia, rats. 
Increased glucagon secretion during hypo- restoration of plasma glucose levels following 
glycaemia is a primary factor responsible for the insulin administration (Cryer 1981). Insulin- 
induced hypoglycaemia activates both para- 
sympathetic (Schwartz et al. 1978, Have1 et al. Correspondence: Dr Bo Ahren, Department Of 
Medicine, Lund University, Malmo General Hospital, 
S-214 01 Malmo, Sweden. 
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1992a) and sympathetic (Havel et al. 1992b) 
nerves innervating the pancreas and in addition 
produces a neurally mediated (Cantu et al. 1963) 
release of adrenaline from the adrenal medulla 
(Cannon et a/ .  1924, Garber et al. 1978), which 
reaches the pancreas via its arterial blood supply. 
Activation of these three neural inputs to the 
pancreas involves independent neural processes, 
each of which can stimulate glucagon secretion 
(Gerich et al. 1974, Ahren et a/ .  1986, 1987). 
Furthermore, autonomic activation has been 
demonstrated to  mediate the majority of 
hypoglycaemia-induced glucagon secretion in 
rats (Borg et al. 1994, Havel et al. 1994), in  mice 
(Havel et a/. 1993) and in dogs (Briggers et a/. 
1989, Havel et a/ .  1991). T h i s  topic has recently 
been extensively reviewed (Havel & Taborsky 
1989, 1994). 
T h e  glucagon secretory response to hypo- 
glycaemia is impaired in both type 1 and type 2 
diabetes (Gerich e t  ul. 1973, Benson et al. 1977, 
Reynold et al. 1977, Hilsted et al. 1982, Meneilly 
rt al. 1994), and a similar impairment has also 
been demonstrated in experimental diabetes in 
the rat (Patel 1983a, b, 1984a, b, Hertelendy et 
al.1992, Ishida et al. 1993, Powell e t  a/ .  1993). 
T h e  underlying mechanisms responsible for the 
impaired hypoglycaemia-induced glucagon se- 
cretion are poorly understood, although auto- 
nomic neuropathy (Maher et al. 1977) and 
hypoglycaemia-associated autonomic failure 
(Dagago-Jack et al. 1993) have been implicated 
in  clinical situations. Previous studies have shown 
that the adrenaline response to hypoglycaemia is 
impaired (Patel 1983a, Powell et al. 1993), and 
that the glucagon secretory responses to vagal 
nerve activation (Hertelendy et a/. 1992) and 
sympathetic nerve stimulation (Kurose et al. 
1992) are impaired in  diabetic rats, suggesting 
that impaired hypoglycaemia-induced glucagon 
secretion in  diabetes could result from impaired 
sympathoadrenal or cholinergic activation or 
neurotransmission. However, reduced A-cell 
secretory responses to direct stimulation by 
adrenaline or to  the cholinergic neurotransmitter, 
acetylcholine, could also contribute to impaired 
glucagon secretion during hypoglycaemia. 
To investigate this possibility, we examined 
the glucagon secretory responses to  insulin- 
induced hypoglycaemia and to  direct stimulation 
with adrenaline or the cholinergic agonist, 
carbachol, in streptozotocin diabetes. 
METHODS 
Animals. Adult male Sprague-Dawley rats (3% 
400 g; Charles River Laboratory) were used. The rats 
were individually housed and fed a stock diet (Ralston 
Purina) and water ad ltbitum. The light/dark cycle was 
12 h on and 12 h off, with lights on at 06.00 h. The 
animal preparation and experimental protocols were 
approved by the institutional animal use and care 
committee, and were conducted in accordance with 
the National Institutes of Health Guide for the Use 
and Care of Laboratory Animals. 
Inducttun of diabetes. Streptozotocin (Sigma Chemi- 
cal Co., St Louis, MO) was freshly prepared in ice- 
cold 0.05 mol L-' citrate buffer, pH 4.5, and injected 
subcutaneously at  the dose level of 80 mg kg-'. Control 
rats were injected with ice-cold 0.05 mol L-' citrate 
buffer alone. All streptozotocin-treated rats exhibited 
polydipsia, hyperphagia and elevated blood glucose 
levels (Table 1). The experiments were performed 
after 6 weeks. 
Hypuglycaemia experiments. Rats were fasted over- 
night with free access to water. They were anaes- 
thetized with chloral hydrate (350 mg kg-' intra- 
peritoneally) and polyethylene cannulae were inserted 
into a femoral vein (for drug administration) and a 
jugular vein (for blood sampling). Chloral hydrate was 
then continuously infused at 25 mg kg-' min-'. 
Chloral hydrate anaesthesia was chosen because we 
have previously demonstrated that neither para- 
sympathetic nor sympathetic nerve responses to 
hypoglycaemia are affected by this agent, as opposed 
to the marked suppression of autonomic activation 
produced by pentobarbital anaesthesia (unpublished). 
Rats were allowed to stabilize for 30 min after surgery. 
A baseline blood sample was taken and its plasma 
glucose value immediately assessed, then a bolus 
Table 1. Body weight, food and water intake, and 
baseline plasma glucose levels in control and 
streptozotocin-diabetic rats 
Control Diabetic 
Treatment rats rats 
Body W t  (g) 
Initial 364+8 375+7 
Final 521+11 351+5 
Change 157f 12 -24+8* 
Intake 
Food (g day-') 3 2 +  1 70 2" 
Water (mL day-') 61 f 4  291 f 11" 
Plasma glucose 7.8 S_ 0.1 26.2 S_ 0.5" 
(mmol L-') 
Values are rneans+SE. Asterisk indicates a prob- 
ability of random difference of P < 0.001 between the 
groups. 
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injection of regular porcine insulin (Novo Inc., 
Bagsvaerd, Denmark) was given according to 
the formula [2.0 +(plasma glucose level in 
mg dL-'- 100) x 0.021 U kg-'; followed by, in dia- 
betic rats, a continuous intravenous infusion of insulin 
at the dose rate of 5 U kg-' h-' (Pate1 1984a). A new 
blood sample was taken at 30 min, and then, in 
diabetic rats, plasma glucose was determined every 
30 min. When the plasma glucose level had dropped 
to 1.8 mmol L-', a find blood sample was taken. 
Experiments with adrenaline and carbachol. 
Following anaesthesia, insertion of catheters as above 
and a 30 min stabilization period, a blood sample was 
taken and then adrenaline (Sigma) was infused 
intravenously at the dose level of 1200 ng kg-' min-' 
for 20 min. Carbachol (Sigma) was injected rapidly 
intravenously, 40 min after the adrenaline infusion 
had been discontinued, at the dose level of 50 pg kg-l. 
Blood samples were taken after 20 rnin of adrenaline 
infusion and immediately before and at 5 min after 
carbachol injection. 
Assays. Blood samples for glucose determination 
were placed in tubes containing EDTA, whereas 
blood samples for glucagon determination were placed 
in tubes containing EDTA and aprotinin (Sigma). All 
samples were kept on ice until centrifugation at 4 "C 
for 20 min. T h e  plasma was then'decanted and frozen 
at - 20 "C until assayed. Plasma glucose was analysed 
by the glucose oxidase method with a glucose analyser 
(Beckman Instruments, Fullerton, CA). Plasma 
immunoreactive glucagon was measured radio- 
immunochemically with an antibody with high speci- 
ficity for the COOH-terminal portion of the glucagon 
molecule and therefore specific for pancreatic gluc- 
agon, using antisera and reagents supplied by Linco 
Research, St Louis, MO. Cross reactivity to gastro- 
intestinal glucagon-like material (oxyntomodulin) is 
less than 0.1 yo. 
Statistics. Data are presented as mean & SE; either 
as absolute values or as changes in values from the 
value before the respective stimulations. T h e  data 
were not expressed as percent increase, since there 
was no significant correlation between baseline plasma 
glucagon values and the glucagon responses to any of 
the stimulations. Statistical comparisons of means 
within a group were performed with a paired t-test, 
whereas comparisons of means of different groups of 
rats were performed with the Mann-Whitney (/-test. 
R E S U L T S  
Insulin induced hypoglycaemia 
Plasma glucose. Plasma glucose levels at 
the time of experiments, i.e. at 6 weeks 
after streptozotocin injection, were 7.8 
0.1 mmol L-' in control ( n  = 15) and 26.2+ 
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Fig. 1. The  increase of plasma glucagon levels above 
baseline in response to insulin-induced hypoglycaemia 
in control (n = 15) and streptozotocin-diabetic rats 
(n = 12) at 6 weeks after induction of diabetes. 
Means f SE are shown. 
0.5 mmol L-' in diabetic rats ( n  = 12; 
P < 0.001). At 30 min after insulin admin- 
istration, plasma glucose levels were 1.7 
0.1 mmol L-' in control and 1 5 . 8 i  
1.5 mmol L-' in diabetic rats. At the time 
of the final blood sampling in diabetic rats, 
plasma glucose levels were 1 .5 & 0.1 mmol L-'. 
This blood sample was taken 202 & 21 rnin after 
insulin administration. 
Plasma glucagon. Baseline plasma glucagon 
levels were 292f60 pg mL-' in control and 
153* 14 pg mL-l in diabetic rats (n.s.; 
P = 0.180). At 30 min after insulin adminis- 
tration, plasma glucagon levels were increased to 
2175 f 282 pg mL-', i.e. by 1883 f 268 pg mL-' 
( P  < 0.001) in controls, whereas the plasma 
glucagon levels in the diabetics were unchanged 
at 1704  36 pg mL-l (n.s.; P = 0.868). At the 
final blood sample in the diabetic rats, i.e. at 
the equivalent low plasma glucose level as in 
the controls, plasma glucagon levels were 
1195 & 376 pg mL-', i.e. they were increased by 
1042 & 336 pg mL-' ( P  = 0.019). Thus, the in- 
crease in plasma glucagon levels during the 
insulin-induced hypoglycaemia was impaired by - 45% in the diabetics ( P  = 0.0454; Fig. 1). 
Adrenaline infusion 
Plasma glucose. Baseline plasma glucose levels 
were 10.2*0.6 mmol L-' in controls (n  = 16) 
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Fig. 2. The increase of plasma glucagon levels above 
baseline in response to 20 min intravenous infusion of 
adrenaline (1200 ng kg-' min-') in control rats 
(n = 16) and in streptozotocin-diabetic rats (n = 10) 
at 6 weeks after induction of diabetes. Means & SE are 
shown. 
and 27.6.f 1.3 mmol L-' in diabetics ( n  = lo), 
and were not significantly altered by the 20 min 
adrenaline infusion (10.7 k 0.8 mmol L-'; 
A = + 0.5 + 0.6 mmol L-' ; n.s. ; P = 0.492) 
in controls and 27.82 1.3 mmol L-' (A = 
1-0.2k0.9 mmol L-'; n s . ;  P = 0.747) in 
diabetics, respectively. 
Plasma glucagon. During adrenaline infusion, 
plasma glucagon levels increased from 225 f 33 
to 504 f 96 pg mL-', i.e. by 279 f 92 pg mL-' 
in controls ( P  = 0.009) and from 142k34 to 
712+ 135 pg mL-', i.e. by 570f 137 pg mL-' 
in diabetics ( P  = 0.002). Thus, the plasma 
glucagon response to adrenaline was approxi- 
mately doubled in the diabetic rats (P = 0.0452; 
Fig. 2). 
Carbachol injection 
Plasma glucose. Plasma glucose levels were 
slightly reduced at 5 rnin after the rapid 
injection of carbachol from 11.0_+0.8 to 
9.5f 1.1 mmol L-' (A = - 1.5kO.4 mmol L-'; 
P = 0.036) in the controls ( n  = 13), whereas 
they were not significantly altered in the diabetics 
(n = 7), averaging 29.4 2.0 mmol L-' before 
carbachol injection and 27.3 f 2.6 mmol L-' at 
5 rnin after (A = -2.1 f 1.6 mmol L-'; n s . ;  
P = 0.252). 
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Fig. 3. The increase of plasma glucagon levels above 
baseline in response to a rapid intravenous injection of 
the cholinergic agonist carbachol (50 pg kg-') in 
control rats (n = 13) and in streptozotocin-diabetic 
rats (n = 7) at 6 weeks after induction of diabetes. 
Means f SE are shown. 
Plasma glucagon. Plasma glucagon levels 
increased from 414+ 102 to 1625 +243 pg mL-' 
at 5 min after carbachol injection, i.e. by 
121 1 f 208 pg mL-' ( P  < 0.001) in controls, and 
from 205 & 28 to 760 f 263 pg mL-' at 5 min 
after carbachol injection in diabetic rats, i.e. 
by 555 f 242 pg mL-' ( P  = 0.049). Thus, the 
plasma glucagon response to carbachol was 
impaired by - 58% in the diabetic rats 
( P  = 0.028; Fig. 3). 
DISCUSSION 
In this study, the plasma glucagon response to 
insulin-induced hypoglycaemia was impaired by - 45 yo in streptozotocin-diabetic rats at 6 weeks 
after induction of the diabetes. The glucagon 
response in the two groups of rats was determined 
from the plasma glucagon levels obtained when 
severe hypoglycaemia had evolved, which oc- 
curred later in the diabetic rats than in the 
control rats. However, it has previously been 
established that it is primarily the absolute 
glucose level rather than the rate of fall of 
glucose that determines the magnitude of the 
glucagon response to hypoglycaemia (Amiel et 
al. 1987). Previously, Pate1 has demonstrated a 
marked (> 90%) impairment of the glucagon 
response to hypoglycaemia at 12 weeks after 
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streptozotocin (Patel 1983 a), whereas a normal 
glucagon response is seen at 1 6 1 5  days after 
streptozotocin (Patel 1984a). Taken together, 
the results suggest a gradual development of the 
impaired glucagon response in streptozotocin- 
diabetic rats. Similarly, a defect in the glucagon 
response to hypoglycaemia has been demon- 
strated in spontaneously diabetic rats (Powell et 
al. 1993) and in dogs (Have1 et al. 1995) and in 
both type 1 and type 2 diabetic humans (Gerich 
et al. 1973, Benson et al. 1977, Reynold et al. 
1977, Hilsted et al. 1982, Meneilly et al. 1994). 
Therefore, impairment of hypoglycaemia- 
induced glucagon secretion seems to be a general 
phenomenon in diabetes. The  mechanisms under- 
lying this impairment are, however, still poorly 
understood. 
Previous studies in streptozotocin-diabetic rats 
have suggested several different mechanisms 
which could contribute to the impaired glucagon 
response to hypoglycaemia. One possibility is 
that the prolonged hyperglycaemia had reduced 
the number of glucagon producing cells, which 
would lower the amount of released glucagon as 
inferred from studies in the obese hyper- 
glycaemic mouse (Hellman 1965). However, this 
possibility is unlikely in the present study, since 
increased rather than reduced pancreatic content 
of glucagon has been observed in this model of 
diabetes (Tomita et al. 1986). Another reason for 
reduced glucagon secretion in streptozotocin- 
diabetic rats is impaired secretion secondary to 
the reduced plasma adrenaline response to 
hypoglycaemia (Patel 1983a). This is also, 
however, an unlikely explanation since the 
impaired adrenaline response, but not the 
reduced glucagon response, is restored by insulin 
treatment (Patel 1983 b). Another possibility is 
reduced function of the parasympathetic nerves, 
since it has been demonstrated that carbachol 
reverses the impaired plasma glucagon response 
to hypoglycaemia at 80-100 days after strepto- 
zotocin in rats (Patel 1984b). Furthermore, the 
glucagon response to electrical vagal nerve 
activation has been shown to be absent, yet that 
to arginine stimulation is present at 12 weeks 
after streptozotocin (Hertelendy et al. 1992). 
An alternative explanation is that reduced 
A-cell responsiveness to adrenaline or the 
cholinergic neurotransmitter contributes to the 
impaired glucagon responses to hypoglycaemia 
in diabetes. In this study, we examined the 
glucagon secretory responses to direct adrenergic 
Glucagon secretion in diabetes 219 
receptor stimulation by adrenaline and direct 
muscarinic stimulation by the cholinergic 
agonist, carbachol. The  study was performed at 
a time point after streptozotocin (6 weeks) when 
there was - 45% reduction of the glucagon 
response to insulin-induced hypoglycaemia. We 
found that the 20 min infusion of adrenaline did 
not significantly alter the plasma glucose levels 
in the fasted rats, which is different from the 
slight hyperglycaemia observed during this 
period of time in the fed rats (Woodson & Potter, 
1979). In addition, we found that the adrenaline 
infusion increased plasma glucagon levels in 
both control and diabetic rats. The  glucagon 
response to adrenaline was significantly exag- 
gerated compared with control rats. This 
confirms a previous study in diabetic humans, 
who also exhibited hyperresponsive glucagon 
secretion during adrenaline infusion (Benson et 
al. 1977). The  mechanism behind adrenaline- 
induced glucagon secretion involves increased 
formation of cyclic AMP and raised concen- 
tration of cytoplasmic calcium (Johansson et al. 
1989). Whether these signalling pathways are 
altered in streptozotocin-diabetic rats remains, 
however, to be studied. In any case, our results 
suggest that the impaired adrenaline response to 
hypoglycaemia in diabetes (Patel 1983 a) might 
be compensated by an exaggerated A cell 
response to the catecholamine. Therefore, we 
conclude that the reduced A-cell responses to 
direct adrenergic stimulation by adrenaline is 
unlikely to be involved in the deterioration of 
the glucagon response to hypoglycaemia in 
streptozotocin-diabetic rats. 
In  contrast, we did find that the glucagon 
response to carbachol was markedly reduced in 
the streptozotocin-diabetic rats compared with 
the controls. This result is consistent with the 
observation that glucagon secretion in response 
to vagal nerve stimulation is reduced in 
streptozotocin-diabetic rats (Hertelendy et al. 
1992) and suggests that reduced direct 
cholinergic stimulation of glucagon secretion 
from the A-cell could contribute to the impaired 
glucagon response to hypoglycaemia in 
streptozotocin-diabetic rats. The  mechanism 
behind the reduced A cell responsiveness to 
carbachol in streptozotocin-diabetic rats remains 
to be established. I t  is of interest, however, that 
a previous in vitro study in isolated islets derived 
from streptozotocin-diabetic guinea-pigs has 
shown a reduced binding of methylscopolamine 
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to the islets and reduced .acetyl choline- 
stimulated glucagon secretion (Ostenson & Grill 
1985). 
I n  conclusion, our present study shows that a t  
6 weeks after administration of streptozotocin in 
rats, the plasma glucagon response to hypo- 
glycaemia is reduced by - 4506 and that this 
coincides with a reduced glucagon response to  
stimulation with the cholinergic agonist 
carbachol. I n  contrast, the glucagon response to 
adrenaline is exaggerated. The results suggest 
that reduced A-cell responsiveness to cholinergic 
but not to adrenergic stimulation may contribute 
to the impairment of the glucagon response to 
insulin-induced hypoglycaemia in strepto- 
zotocin-diabetic rats. 
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